The Centers for Disease Control and Prevention (CDC) has updated its guidelines for RSV vaccines, specifically focusing on older adults. According to the CDC, adults aged 75 and older should receive a single dose of an RSV vaccine. Additionally, adults between the ages of 60 and 74 may also consider getting vaccinated if they have certain risk factors that make them more susceptible to severe RSV infection.
RSV is a common virus that circulates seasonally and can lead to hospitalizations and even death in older adults. The CDC’s Advisory Committee on Immunization Practices has determined that the benefits of RSV vaccination may not clearly outweigh the potential risks for adults aged 60 to 74 who do not have risk factors for severe RSV. However, individuals in this age group with underlying health conditions or who reside in long-term care facilities may still benefit from vaccination.
It’s important to note that individuals who have already received an RSV vaccine should not receive an additional dose. The updated guidelines were issued in response to higher-than-expected rates of Guillain-Barré syndrome (GBS) associated with the vaccines. GBS can cause symptoms such as tingling, numbness, and muscle weakness, and in severe cases, it can lead to paralysis.
While the overall risk of developing GBS from an RSV vaccine is still low, the CDC is recommending a more targeted approach to vaccination based on age and risk factors. The new guidelines aim to simplify the recommendations and make them easier for healthcare providers to implement.
As of spring 2024, an estimated 20% to 25% of U.S. adults aged 60 and older had received an RSV vaccine. It’s important for individuals to discuss the risks and benefits of vaccination with their healthcare provider to determine the best course of action for their specific situation.
Overall, the CDC’s updated guidelines provide clear recommendations for who should consider receiving an RSV vaccine, taking into account age and individual risk factors. By focusing on those who are most likely to benefit from vaccination, the guidelines aim to improve vaccine coverage in at-risk populations and reduce the burden of RSV infection in older adults.